We are live on ! Find out more
CANF icon

Can-Fite BioPharma American Depositary Shares
CANF

8 hedge funds and large institutions have $149K invested in Can-Fite BioPharma American Depositary Shares in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.23% less ownership

Funds ownership: 6.57% → 2.34% (-4.2%)

43% less funds holding

Funds holding: 14 → 8 (-6)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $273K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 6

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
8
Holders Change
-6
Holders Change %
-42.86%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$132K
2
HRT Financial
HRT Financial
New York
-$60K
3
Virtu Financial
Virtu Financial
New York
-$40K
4
Citigroup
Citigroup
New York
-$17K
5
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$10.9K

CANF Hedge Fund Activity: Q2 2026 in Review

8 of the 8,365 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2026, worth a combined $149K — down 65% from $429K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CANF and 0 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, exiting entirely with an estimated $132K sold.

  • 8 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2026, down from 14 in Q1 2026.
  • Funds reported $149K of Can-Fite BioPharma American Depositary Shares stock for Q2 2026, down 65% quarter-over-quarter.
  • 0 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2026 and 6 closed out, a net change of -6 holders.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2026 was Sabby Management, an estimated $132K sold.

Based on aggregated 13F filings for Q2 2026.